Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients

被引：17
作者：
Bertaggia-Calderara, D. [1 ,2 ,3 ]
Kroll, D. [4 ]
Gerschheimer, C. [1 ,2 ,3 ]
Nicolas, N. [1 ,2 ,3 ]
Nett, P. [4 ]
Stirnimann, G. [4 ]
Alberio, L. [1 ,2 ,3 ]
机构：
[1] Lausanne Univ Hosp, CHUV, Div Hematol, Lausanne, Switzerland
[2] Lausanne Univ Hosp, CHUV, Cent Hematol Lab, Lausanne, Switzerland
[3] Univ Lausanne, Lausanne, Switzerland
[4] Bern Univ Hosp, Dept Visceral Surg & Med, Inselspital, Bern, Switzerland
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2018年 / 40卷 / 01期
关键词：
FACTOR-XA INHIBITOR; VENOUS THROMBOEMBOLISM; IN-VITRO; PHARMACODYNAMICS; PHARMACOKINETICS; REPLACEMENT; ACTIVATION; WARFARIN; SURGERY; IMPACT;
D O I：
10.1111/ijlh.12767
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 12 条
  • [1] Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism
    Arachchillage, D. R. J.
    Efthymiou, M.
    Mackie, I. J.
    Lawrie, A. S.
    Machin, S. J.
    Cohen, H.
    [J]. THROMBOSIS RESEARCH, 2015, 135 (02) : 388 - 393
  • [2] Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
    Cohen, Hannah
    Hunt, Beverley J.
    Efthymiou, Maria
    Arachchillage, Deepa R. J.
    Mackie, Ian J.
    Clawson, Simon
    Sylvestre, Yvonne
    Machin, Samuel J.
    Bertolaccini, Maria L.
    Ruiz-Castellano, Maria
    Muirhead, Nicola
    Dore, Caroline J.
    Khamashta, Munther
    Isenberg, David A.
    [J]. Lancet Haematology, 2016, 3 (09): : E426 - E436
  • [3] Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature
    Douxfils, Jonathan
    Mullier, Francois
    Loosen, Claire
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    [J]. THROMBOSIS RESEARCH, 2012, 130 (06) : 956 - 966
  • [4] In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
    Gerotziafas, G. T.
    Elalamy, I.
    Depasse, F.
    Perzborn, E.
    Samama, M. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (04) : 886 - 888
  • [5] Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure
    Gheorghiade, Mihai
    Thyssen, An
    Zolynas, Robert
    Nadar, Venkatesh K.
    Greenberg, Barry H.
    Mehra, Mandeep
    Sun, Xiang
    Tian, Hong
    Plotnikov, Alexei N.
    Burton, Paul.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (02) : 218 - 226
  • [6] Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
    Graff, Jochen
    von Hentig, Nils
    Misselwitz, Frank
    Kubitza, Dagmar
    Becka, Michael
    Breddin, Hans-Klaus
    Harder, Sebastian
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (11) : 1398 - 1407
  • [7] The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation
    Green, Laura
    Lawrie, Andrew S.
    Patel, Shelain
    Hossain, Fahad
    Chitolie, Andrew
    Mackie, Ian J.
    Haddad, Fares S.
    Machin, Samuel J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (05) : 469 - 476
  • [8] Calibrated automated thrombin generation measurement in clotting plasma
    Hemker, HC
    Giesen, P
    Al Dieri, R
    Regnault, V
    de Smedt, E
    Wagenvoord, R
    Lecompte, T
    Béguin, S
    [J]. PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (01) : 4 - 15
  • [9] Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery
    Kroell, Dino
    Stirnimann, Guido
    Vogt, Andreas
    Lai, Desiree Lin Lee
    Borbely, Yves Michael
    Altmeier, Julia
    Schaedelin, Sabine
    Candinas, Daniel
    Alberio, Lorenzo
    Nett, Philipp C.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1466 - 1475
  • [10] Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
    Mueck, Wolfgang
    Borris, Lars C.
    Dahl, Ola E.
    Haas, Sylvia
    Huisman, MennoV.
    Kakkar, Ajay K.
    Kalebo, Peter
    Muelhofer, Eva
    Misselwitz, Frank
    Eriksson, Bengt I.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) : 453 - 461
12